Results · Apr-Jun 2026 · filed 10 Aug 2026
Ind-Swift Laboratories Q1 FY27 results
BlockbusterBlockbuster: sales up 20% or more & profit up 30% or more on the same quarter last year, with a wider operating margin.
Sales grew 25% to ₹191 crore from ₹153 crore in Apr-Jun 2025.
Operating profit grew 829% to ₹33.4 crore, an operating margin of 17.5% (up 15.1 points from a year ago).
Net profit grew 181% to ₹24.7 crore from ₹8.8 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +13%, net profit +63%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 191.5 | 152.7 | +25% |
| Operating profit (EBITDA) | 33.4 | 3.6 | +829% |
| Operating margin | 17.5% | 2.4% | +15.1 pts |
| Net profit | 24.7 | 8.8 | +181% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The earnings call
Apr–Jun 2026 saw operating income grow 21.16% to ₹186 crore & EBITDA margins expand 1,258 bps to 17.91%. CDMO partnerships with Viatris, Manx & Arrotex commercialized; export own-brands now 57.20% of sales, up from 48% from a year earlier.
The last 7 quarters
Filings that week
- 12 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 12 Aug 2026Announcement under Regulation 30 (LODR)-Monitoring Agency Report
- 12 Aug 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release
- 10 Aug 2026Financial Results For The Quarter Ended June 30, 2026
- 10 Aug 2026Statement Of NIL Deviation Or Variation Under Reg. 32
- 10 Aug 2026Board Meeting Outcome for OUTCOME OF BOARD MEETING DATED AUGUST 10, 2026
- 7 Aug 2026Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
- 7 Aug 2026Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.